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two immunogens based on the stem region of HA from the A/
Equine/Argentina/93(H3N8) inﬂuenza strain: a recombinant pro-
tein expressed in prokaryotic cells (DHAp), and a DNA vaccine
(DHAe). A DNA fragment encoding DHAp was cloned into the
pET22b vector, and the recombinant protein was puriﬁed from in-
clusion bodies. The DHAe coding sequence was cloned into
eukaryotic vectors that were transfected in HEK 293T cells. The
expression of proteins was determined by Western blot assay. The
immunogenicity of both vaccine candidates was studied using
different combination of antigens in mice. Immunizations were
done two times with a three-week interval. The DNA vaccine was
given intramuscularly and the recombinant protein was given
intraperitoneally in incomplete Freund’s adjuvant (Sigma). A group
ofﬁvemice received two immunizationswith 50ugofDNAvaccine;
a second group received two immunizations with 10 ug of recom-
binant protein; a third groupwas primedwith 50 mg of DNAvaccine
and boostedwith 10 ug of recombinant protein; a fourth groupwas
primedwith10ugofproteinandboostedwith50mgofDNAvaccine;
and a ﬁfth group received only PBS. We found that immunization
with twodosesof recombinantproteinwasmore immunogenic that
vaccination with DNA only or combination of DNA and protein. In
order to analyze cross-reactivity of the immune sera, ELISA plates
were coatedwith4HAunits of inﬂuenzastrainsbelonging togroups
1 (H1N1) and 2 (H3N2). Plates coated with recombinant protein
were used as a positive control. Higher antibody titers against vi-
ruses belonging to the same phylogenetic group were observed
when mice were immunized with recombinant protein. However
antibody titers were broader and reacted against viruses belonging
to different phylogenetic groups when mice were immunized with
DNA. Conclusions: Recombinant proteins were expressed correctly
in prokaryotic and eukaryotic systems. Homologous antibody titers
were higher in animals immunized with recombinant proteins,
while DNA immunization induced a heterotypic immune response.
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Equine inﬂuenza (EI) is highly contagious acute respiratory dis-
ease of equines caused by Inﬂuenza A virus belong to the family
Orthomyxoviridae. Like other inﬂuenza viruses, equine inﬂuenza
virus (EIV) show periodic antigenic drift that leads to vaccines
strains becoming redundant. This necessitates regular harmoni-
zation of vaccines and strain substitution. The studies in large
animals for potency testing is difﬁcult and suitable small animal
model is required for testing the protective efﬁcacy of the novel or
updated EI vaccine candidates prior to ﬁnal testing in equines. The
present investigation focuses on use of BALB/c mice for studying
the protective efﬁcacy of inactivated indigenous H3N8 vaccine
subsequent to challenge with EIV. BALB/c mice immunized with
inactivated EI vaccine were challenged through intranasal instil-
lation of EIV @ 2x106.24 EID50 in 20ul volume. Mice were moni-
tored for humoral immune response kinetics (HAI), clinical
examination, virus isolation, qRT-PCR, histopathology and
immunohistochemistry (IHC). Immunized mice showed HAI titre
of 138.67±25.69 after two boosters. Clinically unvaccinated mice
suffered severe respiratory disease and showed respiratorydistress, forced expiration, rufﬂed coat, reduced activity and
crouching at corners at 2-7 days post challenge (dpc) with
6.34±0.21 % weight reduction at 5 dpc, whereas vaccinated mice
showed minimal signs at 2-4 dpc with 3.69±0.13% weight
reduction at 2 dpc. Hematology showed mild leucopenia with
lymphopenia at 7 dpc and lymphocytosis at 3 dpc in unvaccinated
and vaccinated mice, respectively. Gross lesions in unvaccinated
mice after challenge were congestion of nasal mucosa, grayish
mucinous exudate in trachea, severe consolidation (3-4mm 2-3
mm) of lung parenchyma with congestion and gray discoloration
at 2-5 dpc. In comparison, vaccinated mice showed only
congestion of lung parenchyma without consolidation at similar
intervals. Main histopathological changes viz. rhinitis, tracheitis,
necrosis of bronchi and bronchiolar epithelium, peribronchitis
and perivascular cufﬁng of neutrophils and lymphocytes, diffuse
interstitial pneumonia were restricted to respiratory tract in un-
vaccinated mice at 3-5 dpc. Vaccinated mice developed mild
respiratory lesions which resolved rapidly (2-3dpc). Gross and
histopathological scoring revealed that vaccinated mice devel-
oped fewer lesions than unvaccinated mice upon challenge. Un-
vaccinated and vaccinated mice showed similar EIV antigen
distributions in nasal turbinate, trachea and lung, but intensity
and duration of positivity was less in vaccinated mice. Virus
isolation from nasal washings and lung tissues showed less virus
shedding (1.25 log10 EID50/ml) and early clearance (1 dpc) in
vaccinated than unvaccinated mice (5.25 log10 EID50/ml at 1 dpc
and persisted up to 5 dpc). Further, qRT-PCR showed unvacci-
nated mice shed signiﬁcantly more virus in nasal washings and
lungs up to 5 dpc as compared to vaccinated mice which shed
very less virus up to 3 dpc. Thus, it can be concluded from the
present investigations that BALB/c mice is a potential small ani-
mal model for testing EIV vaccine candidates prior to testing in
ﬁnal host. Findings of the study will be discussed in detail during
the presentation.
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Equine inﬂuenza virus (EIV) belongs to the Orthomyxoviridae
family and is responsible for the severe acute respiratory disease
of equine inﬂuenza (EI) in the horse population. Two genotypes of
EIV have been isolated, H7N7 (considered extinct) and, H3N8 that
has diverged into American and the European lineages. The
American lineage further evolves into the Kentucky, South
American, and Florida clade 1 and 2. Currenly, Florida Clade 1 and
2 are the most prevalent genotypes worldwide. In China, four
main EI epizootic events (1970, 1989, 1994 and 2007-2008)
occurred. The analyses showed that all EIV were related and
clustered in a single branch belonged to Florida Clade 2. The
strains present in the vaccine are SouthAfrica/1/2003 and Ibaraki/
1/2007 and, although vaccination is currently implemented in
China, sporadic even of EI were detected during the last years. The
aim of this work is analyze the EIV detected during 2011, 2013 and
2015 in China based on phylogenetic and structural analyses of
hemagglutinin protein.The Data set were constructed by BLAST
analyses with Huabei/1/2007 strain to deﬁned sequences to
compared. One hundred and two HA sequences available in
GenBank were used. The phylogenetic analyses was carried out in
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Tasser online server and, the structure were analyzed with UCSF
Chimera package. The phylogenetic analyses showed that the
Asian EIV population has a geographic division. All Japanese strain
grouped in Florida Clade 1 next to USA strains. The EIV population
frommainland (China, Mongolia, Kazakhstan and India) belong to
Florida Clade 2. Furthermore, a geographic association is
observed. Two EIV population can be shown Indian strains cor-
responding to 2008 and 2011 EI outbreak. In China, the 2007-
2008 strains from a monophyletic cluster. Interesting, the strain
Mongolia/56/2011 evolve to the Mongolia 2011 outbreak and,
similar strain were detected in 2012 in Kazakhstan (South
Kazakhstan/236/2012). The strains detected in China in 2013
(Heinlongjian/SS1/2013 and Xuzhou/01/2013) were linked with
the strains detected in Mongolia in 2012. Mapping the amino acid
(aa) substitution, four differences (V78A, S159N, S162P and
K189Q) are found in Huabei/1/2007 respect to the vaccine strain
Ibaraki/1/2007, three in the antigenic site B (top of the protein)
and one in E. Comparing the vaccine strain against Heinlongjian/
SS1/2013, two extra aa substitution can be seen (A144T and
E198G). Our study support the understanding of the molecular
evolution of H3N8 EIV in Asia and will facilitate future in-
vestigations of the epidemiology of these viruses because, the EIV
strains still evolving in the population. Furthermore, contributes
to the monitoring of vaccines the currently available.
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Pseudotyped viruses (PVs) provide a ﬂexible, safe platform for
fundamental virological studies and antibody/antiviral screening
assays. Generation of inﬂuenza PVs involves co-transfection of
producer cells with plasmids encoding the necessary viral com-
ponents. The pseudotype virus neutralization assay (PVNA) is a
sensitive technique to measure protective antibody responses.
Furthermore, many traditional methodologies (e.g. HI, SRH) detect
only surface glycoprotein binding antibodies whereas the PVNA
quantiﬁes infectivity-neutralizing responses. Two enzymes crucial
for the infectivity of inﬂuenza viruses are; HA-cleaving cellular
proteases and neuraminidase (NA). Transmembrane protease
serine 2 (TMPRSS2) has been shown to cleave group 2 inﬂuenza
HAs in both a native and PV context, including an equine H3 PV.
However the efﬁcacy of alternatives, such as TMPRSS4 and human
airway trypsin-like protease (HAT), has not been tested. In nature,
inﬂuenza NA cleaves sialic acid permitting viral egress. When
generating PVs, an exogenous source of NA (often from Clostridium
perfringens) is typically added for cleavage. However, an endoge-
nous source of NA (i.e. NA encoding plasmid) has rarely been used
in the transfection mix to produce inﬂuenza PVs and not yet tri-
alled for H3. Producing high titre PVs is important as this permits
minimal quantities to be used in PVNAs, and repeat experiments
can be carried out using the same batch of virus, minimising intra-
study variability. Here we investigated the role of different pro-
teases and NAs to optimise the generation of PVs. Initially, inﬂu-
enza PVs were generated via co-transfection of HEK293T/17 cells
with plasmids expressing the A/equine/Richmond/1/2007 inﬂu-
enza H3 HA, HIV gag-pol, ﬁreﬂy luciferase reporter and testendoprotease (with the standard addition of exogenous NA). The
nature and quantity of protease plasmid affected PV titre and so the
optimum was subsequently used in a ﬁve plasmid co-transfection
incorporating a different NA plasmid representative of N1-4, 8 and
9 subtypes. Some, but not all, NA subtype plasmids enabled gen-
eration of PVs with H3 HA and there were notable differences in
production titre. PVs were then taken forward into PVNAs, to
determine whether the presence of NA in the PV envelope in-
ﬂuences antibody neutralization. Results showed that neutraliza-
tion was not impeded by the presence of NA.
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Equine inﬂuenza (EI) is a major respiratory disease of the horse
caused by the highly infectious equine inﬂuenza virus (EIV), out-
breaks of which induce signiﬁcant welfare and economic conse-
quences. EI vaccination is one of the most effective methods of
prevention, with diverse EI vaccines commercially available
worldwide. As for all inﬂuenza viruses, EIV constantly evolves
through antigenic drift in order to evade natural and vaccine im-
munity. Genetic and antigenic variations are monitored by the OIE
(World Organisation for Animal Health) Expert Surveillance Panel
for EI vaccine composition (OIE ESP) in order tomaintain optimal EI
vaccine protection. In 2010, the OIE ESP recommended that EI vac-
cines should contain EIV strains fromboth Florida Clade 1 andClade
2 sublineages (FC1 and FC2, respectively). In this context, up-to date
reference antiserum standards are essential for normalisation of
immunogenicity assays, such as the single radial haemolysis assay
(SRH) and the haemagglutination inhibition (HI) test, for EI vaccines
batch potency assay and efﬁcacy evaluation in clinical trials, and for
diagnostic tests. A biological reference preparation (BRP) equine
antiserum to the FC1 EIV strain A/eq/South Africa/4/03 is currently
available, but none exist for FC2EIV strains. This FC2 BRP is urgently
required. Study aims: to produce and establish a new candidate
equine antiserum speciﬁc to the EIV strain A/eq/Richmond/1/07
(FC2 representative strain) asan European Pharmacopoeia (Ph. Eur.)
BRP and as an OIE-approved International Standard. Objectives &
Results: 1) BRP production: two Welsh mountain ponies, seroneg-
ative for EIV, were successfully immunised against the EIV strain A/
eq/Richmond/1/07byexperimental infection.A total of1.230 litre of
serum was collected from day 14 to day 23 post infection and
titratedby SRHusing the EIV strainA/eq/Richmond/1/07 as antigen.
SRH antibody titres ranged from 144mm2 to 217mm2. 2) BRP
titration and validation: after pooling and inactivation with Beta-
propiolactone, a batch of BRP and SRH/HI antigens will be provided
to up to 10 independent collaborative laboratories for SRH and HI
titration. Individual titrations will be analysed by the EDQM statis-
tics department in order to deﬁne the new FC2 BRP potency titre.
Conclusion: the availability of up-to date reference standards is
essential todevelop, evaluateandstandardise thedifferentmethods
of prevention against EI (e.g. EI vaccines and serological diagnostic
tools). This presentation aims to review the multi-stage process of
production and establishment of a new horse antiserum BRP spe-
ciﬁc to the FC2 representative EIV strain, with results currently
obtained highlighted and pivotal stages presented and discussed.
